Canterbury DHB

Context

Management of non-trial patients

Patients who are not entered into the AML19 trial will be treated with 4 cycles of chemotherapy DA X 2 and HDAC X 2.

Cycle 1

DA 3 + 10

Daunorubicin 60 mg/m2 days 1, 3, and 5 (3 doses).

Cytarabine 100 mg/m2 Q12H days 1–10 (20 doses).

Cycle 2

DA 3 + 8

Daunorubicin 50 mg/m2 days 1, 3, and 5 (3 doses).

Cytarabine 100 mg/m2 Q12H days 1–8 (16 doses).

Cycle 3 and 4

 

Cytarabine 1500 mg/m2 Q12H on days 1, 3, and 5 (6 doses).

References:

About this Canterbury DHB document (32084):

Document Owner:

Ruth Spearing (see Who's Who)

Issue Date:

October 2018

Next Review:

October 2020

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 32084